Revance Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a U.S.-based biotechnology and specialty aesthetics company that was historically listed on the U.S. market, with shares traded on the NASDAQ/NYSE ecosystem before the company was acquired. Its headquarters are in Nashville, Tennessee, United States. For French-speaking investors evaluating the name, Revance built its profile around differentiated aesthetic medicine and botulinum-toxin-based therapeutics, combining an R&D-heavy business model with a commercial platform focused on injectables and skincare-related products. The company traces its origins back to 1999, when it was founded as Essentia Biosystems and later became Revance Therapeutics. Over time, it evolved from a research-driven development organization into a commercial-stage company with a broader aesthetics and therapeutics portfolio. Revance’s core business centered on two primary product lines. The flagship product is DAXXIFY® (daxibotulinumtoxinA-lanm), a neuromodulator first approved for glabellar lines and later expanded into cervical dystonia in adults. The company also commercialized the RHA® Collection of dermal fillers in the United States, giving it an important position in the facial aesthetics category. In investor terms, this created a more balanced portfolio: one brand in the botulinum-toxin segment and another in dermal fillers, both aimed at practitioners in aesthetic medicine. Revance also pursued international and partnership-based opportunities, reflecting a strategy to extend the commercial life of its platforms beyond the U.S. market. From a competitive standpoint, Revance operated in a highly concentrated market dominated by much larger players with strong brands, established physician relationships, and global scale. Its strategy was therefore based on differentiation rather than breadth: product formulation, clinical profile, duration of effect, and targeted commercial execution. DAXXIFY was positioned as an innovation in neuromodulator formulation, while the RHA Collection offered a complementary filler portfolio in a category where brand loyalty and injector preference matter significantly. That combination gave Revance a credible, though niche, market position in medical aesthetics. Recent developments are material. In February 2025, Crown Laboratories completed its acquisition of Revance and the combined business was rebranded as REVANCE, with Nashville as the headquarters. Prior to that transaction, Revance had been reporting continued commercial rollout of DAXXIFY and the RHA Collection, including expansion into therapeutics. The acquisition is the key strategic event that changed the company’s public-market story: investors should now view Revance less as an independent listed biotech and more as a legacy brand and product platform folded into a privately held skincare and aesthetics group in the United States.